Envoy Medical announced that the first three patients enrolled in its pivotal trial for the Acclaim cochlear implant have completed their 12‑month follow‑up visits, marking the first time any participants in the study have reached the primary endpoint required for the company’s planned PMA submission to the U.S. Food and Drug Administration.
The Acclaim device is a fully implanted, water‑resistant system that replaces the external microphone and speech processor used in conventional cochlear implants. Reaching the 12‑month endpoint provides the first set of long‑term safety and effectiveness data that will be used to support the PMA application and, if approved, could position Envoy as the first fully internal cochlear implant on the market.
Full‑year 2025 financial results show revenue of $241,000, up 7.11% from $225,000 in 2024, while the company posted a net loss of $23.76 million, a 14.2% increase from the prior year. Envoy has raised $30 million in a recent public offering and has the option to issue an additional $48 million through warrants, providing a runway through 2028‑2029. The company’s market capitalization is approximately $51 million, and its stock has fallen about 49% over the past year.
Regulatory context includes a December 2025 FDA Warning Letter, which introduces uncertainty, but the company also regained compliance with Nasdaq’s minimum Market Value of Listed Securities requirement. The Acclaim device received Breakthrough Device designation in 2019, and Envoy also markets the Esteem fully implanted active middle ear implant, which has been commercially available since 2010.
Investor sentiment has been mixed: the stock has declined nearly half over the past year, and analysts have issued both sell and buy ratings. Insider buying in February 2026, including purchases by directors and other insiders, suggests confidence in the company’s long‑term prospects despite the recent warning letter and ongoing cash burn.
"We are thrilled to highlight the first wave of trial participants successfully reaching and completing their 12‑month endpoint," said CEO Brent Lucas. "We believe our first‑of‑its‑kind breakthrough technology has the potential to change the perception around how severe to profound hearing loss is treated and potentially increase adoption rates. Now that the trial has been fully enrolled and we are beginning to collect 12‑month data, the future of hearing implants may be closer than you realize."
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.